A heterozygote advantage in genetic conditions like hemochromatosis, sickle cell disease (SCD), and factor V Leiden thrombophilia has been implicated as the driver of the continued segregation of deleterious gene variants in populations. Here, F5 is linked to hemochromatosis type 1.